This report is the second part of a trilogy from a multidisciplinary study which was undertaken to record the relationships between clinical severity and dystrophin gene and protein expression. 
Abstract
This report is the second part of a trilogy from a multidisciplinary study which was undertaken to record the relationships between clinical severity and dystrophin gene and protein expression. The aim in part 2 was to correlate the effect of gene deletions on protein expression in individual patients with well defined clinical phenotypes. Among the DMD patients, most of the deletions/duplications disrupted the open reading frame, but three patients had in frame deletions. Some of the intermediate D/BMD patients had mutations which were frameshifting while others were in frame. All of the deletions/duplications in the BMD patients maintained the open reading frame and 25/26 deletions in typical BMD group 5 started with exon 45 . The deletion of single exon 44 was the most common mutation in patients from groups 1 to 3. Dystrophin was detected in sections and blots from 58% of the DMD patients with a size that was compatible with synthesis from mRNA in which the reading frame had been restored. Certain deletions were particularly associated with the occurrence of limited dystrophin synthesis in DMD patients. For example, 9/11 DMD patients missing single exons had some detectable dystrophin labelling compared with 10/24 who had deletions affecting more than one exon. All patients missing single exon 44 or 45 had some dystrophin. Deletions starting or finishing with exons 3 or 51 (8/ 9) cases were usually associated with dystrophin synthesis whereas those starting or finishing with exons 46 or 52 (11/11) were not. Formal IQ assessments (verbal, performance, and full scores) were available for 47 patients. Mean IQ score among the DMD patients was 83 and no clear relationship was found between gene mutations and IQ. The mutations in patients with a particularly severe deficit of verbal IQ were spread throughout the gene. ( In the preceding paper we considered the trends across the clinical spectrum in a cohort of 100 patients with Xp2l linked muscular dystrophy. In this paper our aim was to study the effects that gene deletions (or duplications) had on protein expression in individual patients with well defined clinical phenotypes.
In part 3 we review what we have found in the context of differential diagnosis and prognosis.
Materials and methods

GENE AND PROTEIN ANALYSIS
The methods used are described in part 1 of this report. The effect of gene deletions on the reading frame was calculated from the data on exon border codon type (1, 2, or 3) provided by Koenig et a14 and Worton and Gillard.7 The size of the dystrophin protein present in muscle samples (the observed size) was estimated by comparing the blot migration distance of the uppermost band in each sample lane with the migration distance of the corresponding band in normal control muscle run on the same blot.8 The normal size was taken to be 427 kDa. The predicted size of the dystrophin protein produced by each patient was considered to be 427 kDa if no gene deletion or duplication was detected. If a mutation was found, the predicted size was estimated from the effect the deletion or duplication was expected to have on the total number of amino acids present. For patients with 'in frame deletions' this was straightforward but the predicted size in patients with ' the uppermost band labelled in each sample lane, which corresponds to the largest polypeptide detected for each patient, some samples did show additional bands of lower size. These might well represent truncated translation products which were terminated prematurely. In this study no DMD patient was found who only produced truncated dystrophin, but occasional examples of this kind of labelling have been seen in our laboratory.
As expected, patients with in frame deletions produced vastly more dystrophin than patients with frameshifting deletions. The observed size of any dystrophin protein in the biopsies was determined from the migration distance of bands on Western blots labelled with the rod MAb Dy4/6D3. The predicted size was estimated from the effect any mutation might have on the total number of amino acids synthesised. For patients with in frame deletions this was straightforward and fig 3A shows that there is good agreement between the predicted and observed sizes in these cases. The situation with patients who had frameshifting deletions is more complicated. For these patients, the predicted size Predicted dystrophin size (kDa) Figure 3 Predicted and observed sizes of dystrophin in patients with in frame deletions (A) and frameshifting deletions (B Dystrophin is found in brain as well as muscle and expression of the dystrophin gene is controlled by different 5' promoters in various cell types or tissues, the full length brain isoform having an alternative first exon."'-5 It is possible that defects in the dystrophin gene might affect brain function just as they affect muscle function, although removal of the brain promoter is compatible with normal intellect.'1-8 The majority of our DMD patients were of below average intelligence and the mean full scale IQ in our cohort was 83. This is in accord with previous reviews, which suggest that the mean IQ for DMD patients is one standard deviation below that of an age matched popu- Many of the DMD patients in this investigation had taken part in a previous study on head circumference and intellectual performance. 29 In that study, the occipitofrontal head circumferences of 64 DMD patients were measured and found to be greater than those of an age matched normal population: 47/64 had relative macrocephaly and 12/64 had absolute macrocephaly. No correlation was found between head circumference and intellectual performance. Preliminary data from unenhanced computerised tomography suggested that large heads were accompanied by an increase in brain size. 29 
